Institute for Quality and Efficiency in Health Care

Dimethyl fumarate for MS: Added benefit is not proven

Dimethyl fumarate (trade name: Tecfidera) has been approved since January 2014 for adults with relapsing remitting multiple sclerosis (RRMS). In an early benefit assessment pursuant to the Act on the Reform of the Market ...

Aug 07, 2014
popularity not rated yet | comments 0

COPD: DMP is largely consistent with guidelines

On 3 January 2014 the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with chronic ...

Jan 08, 2014
popularity not rated yet | comments 0

Afatinib: Added benefit depends on mutation status

Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations ...

Feb 19, 2014
popularity not rated yet | comments 0